Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Telaprevir NDA In Treatment-Naive Hep C Now Planned For 2010

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Vertex Pharmaceuticals expects to have data available from Phase III trials evaluating the protease inhibitor telaprevir in patients with hepatitis C by mid-2010, the company announced Jan. 23. The program was initiated in March

You may also be interested in...

Vertex Phase IIb Data On Telaprevir Support 24-Week Dosing For Hepatitis C

Vertex released positive interim data from Phase IIb studies of its experimental protease inhibitor telaprevir for the treatment of hepatitis C Nov. 2 at the American Association of the Study of Liver Diseases meeting in Boston

Sage's Regulatory Strategy For Zuranolone Remains Uncertain

The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts